CABA vs. HLVX, PRME, TRML, ALLO, RGNX, FATE, IMTX, CCCC, EXAI, and TARS
Should you be buying Cabaletta Bio stock or one of its competitors? The main competitors of Cabaletta Bio include HilleVax (HLVX), Prime Medicine (PRME), Tourmaline Bio (TRML), Allogene Therapeutics (ALLO), REGENXBIO (RGNX), Fate Therapeutics (FATE), Immatics (IMTX), C4 Therapeutics (CCCC), Exscientia (EXAI), and Tarsus Pharmaceuticals (TARS). These companies are all part of the "biological products, except diagnostic" industry.
Cabaletta Bio (NASDAQ:CABA) and HilleVax (NASDAQ:HLVX) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, risk, valuation, profitability, earnings, media sentiment and community ranking.
Cabaletta Bio has a beta of 2.46, indicating that its stock price is 146% more volatile than the S&P 500. Comparatively, HilleVax has a beta of 0.68, indicating that its stock price is 32% less volatile than the S&P 500.
In the previous week, Cabaletta Bio had 2 more articles in the media than HilleVax. MarketBeat recorded 3 mentions for Cabaletta Bio and 1 mentions for HilleVax. HilleVax's average media sentiment score of 1.83 beat Cabaletta Bio's score of 0.77 indicating that HilleVax is being referred to more favorably in the news media.
Cabaletta Bio is trading at a lower price-to-earnings ratio than HilleVax, indicating that it is currently the more affordable of the two stocks.
HilleVax's return on equity of -41.96% beat Cabaletta Bio's return on equity.
Cabaletta Bio presently has a consensus price target of $31.20, suggesting a potential upside of 73.53%. HilleVax has a consensus price target of $30.67, suggesting a potential upside of 76.75%. Given HilleVax's higher possible upside, analysts clearly believe HilleVax is more favorable than Cabaletta Bio.
89.8% of HilleVax shares are held by institutional investors. 12.3% of Cabaletta Bio shares are held by company insiders. Comparatively, 29.3% of HilleVax shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Cabaletta Bio received 63 more outperform votes than HilleVax when rated by MarketBeat users. However, 100.00% of users gave HilleVax an outperform vote while only 67.96% of users gave Cabaletta Bio an outperform vote.
Summary
HilleVax beats Cabaletta Bio on 8 of the 14 factors compared between the two stocks.
Get Cabaletta Bio News Delivered to You Automatically
Sign up to receive the latest news and ratings for CABA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CABA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Cabaletta Bio Competitors List
Related Companies and Tools